Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Towards ultra-high dose rates in proton therapy: an ionoacoustic approach for in vivo dose monitoring

Project description

Advancing proton therapy for cancer

Proton FLASH radiotherapy is an innovative form of radiation therapy that delivers ultra-high doses of radiation in extremely short bursts. This emerging technique is gaining attention for its potential to treat cancer more effectively and with fewer side effects to healthy tissue than conventional radiotherapy. Funded by the Marie Skłodowska-Curie Actions programme, the RAPID project aims to enhance this form of therapy through real-time dose monitoring. Researchers will combine ionoacoustic imaging and ultrasound to study the effects of FLASH therapy on tissues, helping to refine and advance this promising cancer treatment.

Objective

The use of ultra-high dose rates (FLASH) in radiation therapy has emerged as a promising modality to treat cancer due to its unprecedented ability to reduce healthy tissue toxicity while ensuring tumor control. “Towards ultra-high dose RAtes in Proton therapy: an Ionoacoustic approach for in vivo Dose monitoring” (RAPID) project aims at providing new insights into the clinical benefits of proton FLASH radiotherapy by resolving the challenge of real-time dose monitoring. The action represents a powerful instrument to push the boundaries of cancer care with proton radiotherapy at three different levels: i) the optimization of an ionoacoustic imaging system for real-time pulse-based 3D dose monitoring, ii) the experimental evaluation of the physical requirements to achieve the FLASH effect by in vivo and in vitro studies under different beam conditions, and iii) the interpretation and optimization of the ionoacoustic signal response for different treatment plans. The ionoacoustic imaging technique, combined with an ultrasound system, will enable to image simultaneously tissue morphology and dose deposition of the beam. These technological advances will disentangle the complex and multiple variables influencing the yet unknown FLASH effect, as well as enabling the first systematic study combining FLASH dosimetry and tissue damage/toxicity response. The researcher will spend 24 months at the Department of Radiation Oncology at Massachusetts General Hospital and Harvard Medical School (Boston, USA) and 12 months at the Department of Atomic, Molecular and Nuclear Physics at University of Seville (USE, Spain) and Centro Nacional de Aceleradores – National Center of Accelerators, an USE joint research center.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

UNIVERSIDAD DE SEVILLA
Net EU contribution
€ 285 140,64
Address
CALLE S. FERNANDO 4
41004 Sevilla
Spain
Region
Sur Andalucía Sevilla
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (2)